PE20070435A1 - Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa - Google Patents

Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa

Info

Publication number
PE20070435A1
PE20070435A1 PE2006001126A PE2006001126A PE20070435A1 PE 20070435 A1 PE20070435 A1 PE 20070435A1 PE 2006001126 A PE2006001126 A PE 2006001126A PE 2006001126 A PE2006001126 A PE 2006001126A PE 20070435 A1 PE20070435 A1 PE 20070435A1
Authority
PE
Peru
Prior art keywords
prostama
cancer
protein kinase
pharmaceutical formulation
inhibitor
Prior art date
Application number
PE2006001126A
Other languages
English (en)
Inventor
Cecil B Pickett
Bishop Walter Robert
Yaolin Wang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070435(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070435A1 publication Critical patent/PE20070435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA QUE COMPRENDE: A) TEMOZOLOMIDA (TMZ) EN UNA INTENSIDAD DE DOSIS ESTANDAR O AUMENTADA, EN COMBINACION CON B) UN INHIBIDOR DE LA PROTEINA QUINASA C (PKC), PREFERENTEMENTE UN INHIBIDOR SELECTIVO DE LA PKC BETA TAL COMO: RUBOXISTAURINA (LY333531), O N-DESMETIL LY333531 ENCONTRANDOSE EN UNA CANTIDAD APROXIMADA DE 0,1 MG A 1,5 MG POR DIA POR KG DE PESO CORPORAL; ENZASTAURINA (LY317615), LY326020 ENCONTRANDOSE EN UNA CANTIDAD APROXIMADA DE 250 MG A 1000MG POR DIA; O LY379196. TAMBIEN SE REFIERE A UN KIT QUE COMPRENDE DICHA FORMULACION, EL CUAL ES UTIL PARA EL TRATAMIENTO DE ENFERMEDAD PROLIFERATIVA CELULAR TAL COMO GLIOMA TAL COMO ASTROCITOMA ANAPLASICO O GLIOBLASTOMA MULTIFORME, CANCER DE PROSTATA, PULMON, MAMA, ENTRE OTROS
PE2006001126A 2005-09-16 2006-09-15 Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa PE20070435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71801105P 2005-09-16 2005-09-16

Publications (1)

Publication Number Publication Date
PE20070435A1 true PE20070435A1 (es) 2007-06-13

Family

ID=37865608

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001126A PE20070435A1 (es) 2005-09-16 2006-09-15 Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa

Country Status (8)

Country Link
US (1) US20070112053A1 (es)
EP (1) EP1940395A2 (es)
JP (1) JP2009508868A (es)
AR (1) AR056517A1 (es)
CA (1) CA2622867A1 (es)
PE (1) PE20070435A1 (es)
TW (1) TW200803849A (es)
WO (1) WO2007033374A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
DK3290035T3 (da) 2012-03-06 2019-08-05 Univ Illinois Procaspase-kombinationsterapi til behandling af cancer
KR20140087846A (ko) * 2012-12-31 2014-07-09 주식회사 삼양바이오팜 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
EP3691632A4 (en) * 2017-10-06 2021-05-26 Research Cancer Institute of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS
WO2019099873A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE3827974A1 (de) 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4990519A (en) 1988-10-24 1991-02-05 Merrell Dow Pharmaceuticals Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors
US5141957A (en) 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5204370A (en) 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
US5216014A (en) 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
US5270310A (en) 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1995011222A1 (en) 1993-10-18 1995-04-27 Virginia Tech Intellectual Properties, Inc. Synthesis of sphingosines
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5616577A (en) 1994-08-25 1997-04-01 Smithkline Beecham Corporation Protein Kinase C inhibitor
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
NZ538686A (en) * 2002-09-23 2008-01-31 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
US20050148643A1 (en) * 2003-08-19 2005-07-07 Agouron Pharmaceuticals, Inc. Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme

Also Published As

Publication number Publication date
TW200803849A (en) 2008-01-16
JP2009508868A (ja) 2009-03-05
EP1940395A2 (en) 2008-07-09
WO2007033374A2 (en) 2007-03-22
WO2007033374A3 (en) 2007-07-26
AR056517A1 (es) 2007-10-10
CA2622867A1 (en) 2007-03-22
US20070112053A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
PE20070435A1 (es) Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa
AR052190A1 (es) Uso de clorantes de cianina para el diagnostico de enfermedades proliferativas
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
GT200600046A (es) Terapia de combinacion
DOP2002000438A (es) Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CL2007000797A1 (es) Composicion farmaceutica que comprende entre alrededor de 1 y 150 mg/ml de humab igf-1r, entre alrededor de 0,001 y 1% de al menos un humectante, entre alredededor de 1 y 100 mm de un tapon a un ph entre alrededor de 5 y 7; y uso para el tratamiento de cancer de mama, cancer de pulmon y de prostata
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
PE20080907A1 (es) Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
SV2007002146A (es) Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727
ECSP088220A (es) Uso de dosis única de moléculas de unión específica cd20
CL2008001303A1 (es) Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
GT200500113A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
PA8616801A1 (es) Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos
TR201901390T4 (tr) Demodikoza karşı madde.
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
UY29417A1 (es) Agentes endoparasiticidas
UY28925A1 (es) Nuevos derivados de aminopiridina y su uso como fármacos
PT1824504E (pt) Combinações antitumorais contendo vegf-trap e 5fu ou um de seus derivados

Legal Events

Date Code Title Description
FC Refusal